多西紫杉醇联合沙立度胺片二线治疗晚期非小细胞肺癌的临床观察

Clinical Observation on Thalidomide Accompanied Docetaxel in Chemotherapy Patients with Advanced Non-small Cell Lung Cancer As Second-line Chemotherapy

目的评价多西紫杉醇联合沙立度胺片二线治疗晚期非小细胞肺癌(NSCLC)的疗效和不良反应。方法采用同期随机对照方法,共85例晚期复发的NSCLC患者入组。46例患者接受多西紫杉醇联合沙立度胺片二线治疗(治疗组),39例患者接受多西紫杉醇单药二线治疗(对照组)。结果治疗组和对照组的有效率分别为19.6%和17.9%,疾病控制率分别为65.3%和56.4%,中位无进展生存期(PFS)分别为5月和3月(P=0.029),中位生存期(OS)分别为9月和6月(P=0.044)。两组常见的不良反应是骨髓抑制、消化道反应、脱发、乏力、关节酸、嗜睡、便秘、水肿及末梢神经炎等,治疗组和对照组的差异无统计学意义(P>0.05)。结论多西紫杉醇联合沙立度胺片二线治疗期NSCLC,能够延长生存时间,提高生存质量,改善预后,且不良反应无明显增加。

Objective To evaluate the therapeutic effects and toxicities of docetaxel plus thalidomide for the treatment of advanced non-small cell lung cancer as second-line chemotherapy.Methods This study was carried out as a prospective,randomized control clinical trial.46 patients with advanced non-small cell lung cancer were scheduled to receive chemotherapy（docetaxel plus thalidomide）as treatment group,39 patients were scheduled to receive chemotherapy（docetaxel only）as control group.Results The median time to disease progression was 5 months and 3 months（P=0.029）.The median survival time was 9 months and 6 months（P=0.044）.There were statistically significant differences between the two groups（P0.05）.Two groups of common adverse reaction were bone marrow suppression,digestive tract,hair loss,fatigue,reaction joint acid,lethargy,constipation,edema and peripheral neuropathy,etc.The difference of the treatment group and control group was of no statistical significance（P0.05）.ConclusionThalidomide accompanied docetaxel in advanced NSCLC is active effect,it can prolong survival time significantly and improve patient＇s life quality.